deferasirox has been researched along with Leukemia, Myelomonocytic, Acute in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujita, Y; Fukushima, T; Hirose, Y; Iwao, H; Kawabata, H; Masaki, Y; Miki, M; Nakajima, A; Nakamura, T; Sakai, T; Sawaki, T; Tanaka, M; Umehara, H | 1 |
1 other study(ies) available for deferasirox and Leukemia, Myelomonocytic, Acute
| Article | Year |
|---|---|
Iron chelation therapy with deferasirox induced complete remission in a patient with chemotherapy-resistant acute monocytic leukemia.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzoates; Chelation Therapy; Deferasirox; Drug Resistance, Neoplasm; Erythrocyte Transfusion; Gemtuzumab; Humans; Iron Chelating Agents; Leukemia, Myelomonocytic, Acute; Male; Remission Induction; Salvage Therapy; Treatment Outcome; Triazoles | 2011 |